Gary Palgon | Liaison Technologies
A new model of aggregating, harmonizing and analyzing healthcare data is giving pharma companies unprecedented ability to both reduce development costs and to accelerate the time bringing new drugs to market.
Called dPaaS for Data Platform as a Service cloud-based model puts the focus on data being at the center of the business universe rather than applications. This means that regardless of what application is required, access to data is always available. More often than not today, we have applications that create boundaries around data rather than making data accessible for all business needs. Not only does dPaaS provide maximum flexibility and scale for pharma researchers, but it allows expert scientists to use their time and skills wisely toward actual drug development, rather than serving as high-cost “data janitors” in cleaning and preparing their data for analysis.